Branded Drug pricing Increased 158% Over Past 7 Years Compared To CPI Of 12%: Morgan Stanley

Hillary Clinton’s proposal to constitute a drug price task force following Mylan’s EpiPen pricing will focus on non-innovator BioPharma, according to Morgan Stanley. David Risinger and team point out in their September 7 research piece titled “Epipen controversy drives renewed drug price scrutiny” that R&D productivity has stepped dramatically higher in recent years with new molecular and new biological entity approvals hitting a 19-year high of 45 last year.

Epipen controversy reignites drug price scrutiny

Mylan’s EpiPen delivers a shot used to fight life-threatening allergic reactions to food, insect bites and other allergens. Mylan raised the price from $100 to $500 recently, inciting public wrath. Recently two senators called on Mylan to explain the price increase and asked the FTC to look...